Author: Oleksandr Pylypenko

Oleksandr began writing for Market Realist in 2019. He's a founder of an investment research team focused on biotech companies that represents a lot of "shots" on goal. He focuses his trade strategy around "special situations" (such as catalysts, potential acquisitions, or spin-offs) and how to make money from those catalysts, as direct stock purchases, combined with option-based approaches for risk minimization.

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.

In the November 14 trading session, Aurora Cannabis (ACB) stock fell 12.7% from the previous session during after-hours trading.

Some options traders are betting large, bullish bets in favor of Disney stock and Disney+ in particular. Let’s take a closer look at the options.

Since my last article about Nvidia (NVDA), the stock has risen from $196.86 to $208.57. I expect a further rise after today's earnings results.

During the Golden Steering Wheel awards ceremony, Tesla’s (TSLA) CEO Elon Musk revealed that Berlin was selected for the company's next Gigafactory.

Energy Transfer stock (ET) has been under pressure due to a weak earnings season from MLPs, but its fundamentals are stronger than ever.

Shares of Aurora Cannabis rose 6.42% on November 8. Pricing pressure could remain a concern for the company ahead of its earnings release.

AMD shares have appreciated since the Q3 earnings release. But is it worth investing right now, given AMD's high price-to-earnings multiple?

Let's take a look at three big tech stocks— Alphabet (GOOGL), Apple (AAPL), and Fitbit (FIT)—to see what's driving them right now.

In the November 1 trading session, Twitter stock (TWTR) is trading at $29.64, down 1.10% from the previous session. Is now the time to buy?